Home › Sovrappeso › Alabama › Birmingham
Studi clinici su Sovrappeso a Birmingham, AL
16 studi su Sovrappeso cercano partecipanti presso sedi a Birmingham e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
In reclutamentoFase 3
- Univ of Alabama Birmingham, Birmingham
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
In reclutamentoFase 2
- University of Alabama - Birmingham, Birmingham
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
In reclutamentoFase 3
- Univ of Alabama Birmingham, Birmingham
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
In reclutamentoFase 3
- Central Research Associates, Birmingham
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
In reclutamentoFase 3
- Birmingham Clinical Research, Birmingham
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
In reclutamentoFase 3
- Birmingham Clinical Research, Birmingham
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
In reclutamentoFase 3
- AURORA-1 Clinical Site, Birmingham
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
In reclutamentoFase 3
- AURORA-2 Clinical Site, Birmingham
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
In reclutamentoFase 3
- Alabama Clinical Therapeutics, Birmingham
- University of Alabama at Birmingham, Birmingham
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
In reclutamentoFase 3Volontari sani benvenuti
- ACCOMPLISH-2 Research Site, Birmingham
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
In reclutamentoFase 3
- Uni of Alabama at Birmingham, Birmingham
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
In reclutamentoFase 3
- Kailera Clinical Site, Birmingham
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
In reclutamentoFase 3
- ACCOMPLISH-1 Research Site, Birmingham
- ACCOMPLISH-1 Research Site, Birmingham
Time-restricted Eating for Postpartum Weight Loss
In reclutamento
- University of Alabama at Birmingham, Birmingham
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
In reclutamento
- University of Alabama at Birmingham, Birmingham
FELLAShip to Better Health
In reclutamento
- The Worship Center Cristian Church, Birmingham
Studi su Sovrappeso in altre città
- San Antonio, TX34 studi
- Houston, TX33 studi
- Chicago, IL28 studi
- Orlando, FL27 studi
- Las Vegas, NV23 studi
- Miami, FL23 studi
- Atlanta, GA20 studi
- Dallas, TX20 studi
- New York City, NY19 studi
- Jacksonville, FL19 studi
- Washington, DC19 studi
- Austin, TX18 studi
Altri studi a Birmingham
- Cancro (tutti i tipi)30 studi
- Cancro al seno24 studi
- Obesità23 studi
- Cancro ovarico23 studi
- Cancro del polmone non a piccole cellule22 studi
- Leucemia mieloide acuta21 studi
- Mieloma multiplo18 studi
- BPCO17 studi
- Malattie cardiovascolari17 studi
- Cancro dell'endometrio16 studi
- Diabete di tipo 216 studi
- Fibrosi cistica16 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.